COPD is associated with poorer survival in patients with advanced non-small cell lung cancer treated with first-line ICI plus chemotherapy.
Lung disease worsens outcomes for cancer patients receiving immunotherapy, highlighting the need for careful comorbidity assessment in treatment planning.
Comorbid COPD is an independent negative prognostic factor for survival in advanced NSCLC receiving first-line ICI + chemotherapy, supporting COPD as a key patient stratification variable for ICI-based regimens. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective_cohort
- Category
- novel_therapeutics
- Maturity
- Validated
- Journal
- BMC Pulmonary Medicine
Why it surfaced
Prognostic impact of COPD comorbidity on ICI+chemo outcomes in NSCLC; relevant to patient stratification for novel immunotherapy regimens.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.